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Abstract
Tumor-derived exosomes (TDEs) play a pivotal role in tumor establishment and progression, and are emerging
biomarkers for tumor diagnosis in personalized medicine. To date, there is a lack of efficient technology platforms
for exosome isolation and characterization. Multiple myeloma (MM) is an incurable B-cell malignancy due to the
rapid development of drug-resistance. MM-released exosomes express the immunoglobulin B-cell receptor (Ig-BCR)
of the tumor B-cells, which can be targeted by Idiotype-binding peptides (Id-peptides). In this study, we analyzed
the production of MM-released exosomes in the murine 5T33MM multiple myeloma model as biomarkers of tumor
growth. To this end, we selected Id-peptides by screening a phage display library using as bait the Ig-BCR expressed by
5T33MM cells. By FACS, the FITC-conjugated Id-peptides detected the MM-released exosomes in the serum of 5T33MM-
engrafted mice, levels of which are correlated with tumor progression at an earlier time point compared to
serum paraprotein. These results indicate that Id-peptide-based recognition of MM-released exosomes may
represent a very sensitive diagnostic approach for clinical evaluation of disease progression.
Background
Multiple myeloma (MM) is a clonal B-cell malignancy
accounting for more than 10% of hematologic cancers, and
is characterized by the aberrant expansion of bone marrow
plasma cells releasing a high level of monoclonal immuno-
globulin (mIg) in the blood, so called paraprotein [1]. MM
remains largely incurable due to the rapid development of
aggressive, drug-resistant phenotypes [2]. Monitoring MM
progression is a crucial step for determining the stage of
disease and choosing the most appropriate therapy. In this
context, there is an urgent need to develop novel diagnostic
approaches allowing the non-invasive early detection of
tumor growth and the efficient monitoring of tumor
progression [3].
First identified in the mid-80s [4] and initially classified
as unfunctional “garbage bags” containing unwanted cellu-
lar constituents, exosomes represent a promising tool for
novel diagnostic options in the diagnosis of malignant
diseases [5]. Indeed, recent evidence demonstrated the
utility of microvesicles in detecting relapse weeks before
existing clinical tests, highlighting the sensitivity and
capacity for microvesicles in monitoring disease progres-
sion and minimal residual disease in myeloma patients [6].
Exosomes are vesicles of 30–130 nm in diameter released
by different cell types and detectable in all biological fluids
[7] and supernatants of cultured cells [8]. Exosomes
contain a wide range of RNA and proteins, playing an
important role in cell-to-cell communication [9]. In par-
ticular, exosomes are involved in the regulation of the
immune response, antigen presentation [10], tumor
survival [11], cell migration [12], tumor invasion [13], cell
differentiation and angiogenesis [14]. Reflecting the
genomic and proteomic profile of their parental cells,
circulating serum exosomes are potential biomarkers in
predicting cancer burden with relevant impact for person-
alized therapy [15]. Although several methods have been
developed for exosome purification, none of them clearly
distinguish between normal and tumor-derived exosomes
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(TDEs), or avoid contamination by shed membrane vesci-
cles [16]. Even if the mechanism of expression remains
not completely defined, it is worthwhile that MM-released
exosomes constitutively express on their surface the im-
munoglobulin of B-cell receptor (Ig-BCR) derived from
the parental tumor B-cell, and thus they can be reliable
tumor markers [17, 18].
In the last few years, we successfully validated the
screening of random peptide libraries (RPLs) as a
method to identify peptides binders of soluble immuno-
globulins (Igs) [19] transmembrane receptors [20, 21]
and biomaterials [22]. In particular, we identified peptide
binders of the Ig-BCR idiotypic determinants (hereafter
named “Id-peptides”) that are expressed on the surface
of the A20 murine B-cell lymphoma, which revealed to
be sensitive tools for in vivo tumor detection and tumor-
specific delivery of radionuclides, fluorophores, siRNAs
and nanoparticles [23].
In this study, we addressed the question whether MM-
released exosomes detected by Id-peptides could allow a
more efficient monitoring of tumor growth compared to
the standard paraprotein assay. To this end, we mea-
sured the tumor growth and serum MM-released exo-
somes in vivo in the 5T33MM murine model [24].
5T33MM-engrafted mice develop a highly aggressive
MM form, presenting biological and genetic characteris-
tics similar to the human disease, and thus it represents
one of the most reliable MM preclinical model [25].
Methods
Cell lines and immunoglobulin purification
5T33MM, A20 and IM9 B cell lines bear surface Igs that
are secreted in the culture medium. Cells were grown in
RPMI medium, supplemented with 10% fetal bovine
serum, 50 units/ml penicillin, 50 μg/ml streptomycin
and 2 mM L-glutamine.
B-cells from MM patient and healthy donor were
isolated by negative selection from whole blood using
RosetteSep Human B Cell Enrichment Cocktail [Stem
Cell Technology, Vancouver, Canada], as previously
described [26].
Igs were purified from the culture supernatants by
using the Mab Trap™ antibody purification Kit [GE
Healthcare, Little Chalfont, UK], according to the manu-
facturer’s instructions.
Selection and amplification of phage ligands of 5T33MM Ig
The Ph.D.-C7C Phage Display Peptide Library kit was
purchased from New England Biolabs [NEB, Ipswich,
Massachusetts, US]. The screening of phage displayed li-
brary was performed using the bait 5T33MM Igs, as previ-
ously reported [22]. Briefly, the streptavidin-conjugated
beads [Thermo Fisher, Waltham, Massachusetts, US] were
coated with 5T33MM Igs and incubated with 1 × 1011
phages overnight at 4 °C. Beads were extensively washed
with PBS supplemented with 0.05% Tween-20 to remove
unbound phage. 5T33MM Igs-interacting phages were
eluted with 0.2 M glycine-HCl (pH 2.2, 1 mg/mL BSA)
followed by the addition of neutralizing solution (1 M
Tris-HCl pH 9.1). Ultimately, 3 cycles of panning were
performed. Plaques of lysis from isolated phages were
transferred to nitrocellulose filters, and membranes were
blocked with PBS 1X, 0.1% NP-40; 5% milk; 0.02% NaN3
and then incubated for 2 h at RT with 100 μg of purified
5T33MM Igs. After washing, membranes were hybridized
with an alkaline phosphatase-conjugated anti-mouse IgG
[Sigma Aldrich, Saint Louis, Missouri, US] (dilution
1:5000) and then washed 6 times. Immunoreactive phage
clones were detected by BCIP/NBT premixed substrate
[Thermo Fisher].
Synthesis and in vitro evaluation of id-peptides binding
to the 5T33MM Ig
Single strand DNA (ssDNA) was extracted from the
selected phage clones by phenol/chlorophorm purifica-
tion followed by ethanol precipitation. DNA fragment
codifying the peptide ligand was amplified by PCR and
sequenced to get the primary structure of amino acid
sequence for the peptide synthesis. Synthesized peptides
were purchased from Caslo Laboratory ApS [Caslo,
Kongens Lyngby, DE]. The specific binding of peptides
to the 5T33MM sIgG was analyzed by ELISA, as follows.
Streptavidin coated 96 well plates were washed exten-
sively and supplemented with biotin-conjugated peptides
by 1 h-incubation at 37 °C; then, after washing and
blocking with blocking solution (1X PBS, 0.05%
Tween-20, 5% milk), aliquots of 5T33MM sIgG (1 μg/
ml in blocking buffer) were added overnight at 4 °C.
Wells were extensively washed and coated with the
anti-mouse IgG (Fc-specific) alkaline phosphatase-
conjugated [Sigma Aldrich] for 1 h at 37 °C, incu-
bated with the alkaline phosphatase substrate [Sigma
Aldrich], and analyzed by an ELISA reader at 405 nm
[Labsystems multiscan MS].
In vitro cell binding
Cultured 5T33MM, A20 and IM9 cells as well as primary
B cells from MM patient and healthy donor were washed
and suspended at the density of 106 cells/ml in FACs Flow
Buffer [BD Biosciences]. All subsequent washing and incu-
bations were carried out in the same buffer on ice. Cells
were incubated with 20 μg/ml of FITC-conjugated pep-
tides for 10 min on ice, then washed twice, and analyzed
by flow cytometry [FACSCalibur, BD Biosciences]. For
peptide co-localization with the BCR complex, 5T33MM
cells (106 cells/ml) were stained with FITC-conjugated
peptides [10 μg/ml) and goat anti-mouse IgG-Alexa fluor
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568 [Thermo Fisher]. After extensive washing, cells were
mounted under cover slip, and visualized by confocal
microscopy [Leica TC-SP2].
Animal studies
Experiments were conducted in C57BL/KaLwRij mice (8
to 10 weeks-old females) in accordance with the National
Institutes of Health Guide for the Care and Use of Labora-
tory Animals. A total number of 10 mice per group were
respectively injected with 106 cells of 5T33MM multiple
myeloma cells or A20 B-lymphoma cells. Whole blood
samples (250 μL) were collected at baseline and then
weekly after tumor inoculation by retro-orbital bleeding.
Isolation of MM-released exosomes
Exosomes were isolated from 250 μL of blood and 10 mL
of cell supernatant respectively using ExoQuick solutions
[System Biosciences – SBI, Palo Alto, California, US] and
Fig. 1 Workflow of the experimental design. The Igs secreted by 5T33MM cells were purified from cell supernatant using Protein G affinity
chromatography, and used as bait to isolate phage ligands from the C7C phage-displayed peptide library fused to the M13 minor coat protein.
ELISA was performed to select ligands with distinct affinities for their cognate Ig-BCR. Synthetic peptides corresponding to the peptide insert of
phage clones were assayed for their antigenic properties out of the phage context. The purified 5T33MM-released exosomes were characterized
by scanning electron microscopy (SEM), Zetasizer and Western blotting analysis. SMNPs were decorated with biotinylated anti-CD63, incubated
with RED-EXO-labeled exosomes, and analyzed for the binding of FITC-conjugated Id-peptides by flow cytometry. For in vivo analysis, 5T33MM
cells (1 × 106) were intravenously injected in C57BL/KaLwRij mice (10 females at 8 weeks of age). Tumor-derived exosomes and paraprotein levels
in peripheral blood were monitored every 7 days up to 35 days post-inoculation
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ExoQuick-TC™ [System Biosciences], according to the
manufacturer’s protocol. Briefly, serum and cell superna-
tants were centrifuged at 3000×g for 15 min to remove
cells and cell debris. The supernatant was transferred to a
sterile vessel and the recommended volume of ExoQuick
solution or ExoQuick-TC™ were added to the bio-fluids.
After brief vortex, samples were stored 30 min at 4 °C and
then centrifuged at 1500 x g for 30 min at room
temperature. After removing the supernatant, the pellet
was suspended in nuclease-free water.
Detection of MM-released paraprotein
The levels of serum IgG2b from the blood (250 μL) of
tumor-engrafted mice or control mice were measured
using the Easy-Titer™ Mouse IgG Assay Kit [Thermo
Fisher] according to manufacturer’s instructions.
Physical characterization of exosomes
The exosomes sample (10 μl) was spread, evaporated by
using a vacuum concentrator at 30 °C, and analyzed by
scanning electron microscopy [ESEM Quanta 400 in-
strument; FEI]. Dynamic light scattering and zeta poten-
tial determinations were performed with a Nano ZS 90
[Malvern Instruments], allowing the analysis of particles
within the range of 1 nm up to 3 μm. For Western blot
analysis, the exosomes were lysed in reducing sample
buffer [0.25 M Tris–HCl (pH 6.8), 40% glycerol, 8%
SDS, 5% 2-mercaptoethanol and 0.04% bromophenol
blue] and boiled for 10 min at 95 °C. Proteins were re-
solved by SDS-PAGE (SDS-polyacrylamide gel electro-
phoresis), transferred to poly-vinylidene fluoride
membranes, blocked with 5% non-fat powdered milk in
PBS-T (0.5% Tween-20) and probed with anti-mouse
CD63, anti- mouse CD81, or anti-mouse IgG antibodies.
Fig. 2 In vitro binding of selected Id-peptides to the 5T33MM-Ig. a Concentration-dependent binding of N-biotinylated synthetic Id-peptides to purified
5T33MM-Ig as determined by ELISA. Peptide binding to A20 secreted Igs and polyclonal mouse Igs were included as controls. b Concentration-dependent
binding of FITC-conjugated p5 peptide and relative control peptide to 5T33MM cells, as measured by flow cytometry. c Representative confocal images of
5T33MM cells labeled with FITC-conjugated p5 peptide (green), stained with the APC-conjugated anti-mouse IgG antibody (white), and DAPI (blue). The
analysis was performed using a Leica TCS SP2 confocal microscope at 40X magnification
Table 1 Characteristics of 5T33MM Id-peptides
Id-peptide name Sequence (aa)a Freq. (%)b KD (nM)c
p5 CIGNSNTLC 38,4 6,29
p8 CTVRTSADC 23,2 15.4
p2 CSNNGNALC 15,4 47,3
p4 CISNGNQPC 15,4 64,2
p3 CRVNTAALC 7,6 77,7
(a) Recombinant peptide insert displayed by C7C phage-displayed RPL
(b) Percentage of independent clones isolated at the end of three
biopanning cycles
(c) KD values for the Id-peptides binding to the cognate mIg-5T33MM, as esti-
mated by Scatchard plot analysis
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Protein bands were detected using X-ray film and
enhanced chemiluminescence reagent [GE Healthcare].
Exosome immunocapture and flow cytometry
Isolated exosomes from serum or cell supernatants were
suspended in 1 ml of 1X PBS. Exosome aliquots (500 μl)
were labeled with 50 μl of 10X Exo-Red [SBI] according
to manufacturer’s instructions. The exosomes were
re-isolated using the addition of 100 μl ExoQuick
followed by precipitation for 30 min at +4 °C. The
labeled exosome pellet was suspended in 500 μl 1X PBS
and stained with CD63-coupled magnetic beads pro-
vided by SBI’s Exo-Flow IP kit [SBI] and with the FITC-
conjugated peptides.
Results and discussion
The experimental plan undertaken is shown in Fig. 1.
Briefly, we screened a C7C M13 phage-displayed RPL
[NEB] using as bait the Igs isolated from cultured
5T33MM cells. The random peptide insert was flanked by
a pair of cysteines resulting in cyclized peptide exposed on
M13 coat protein. After three rounds of affinity selection,
single phage clones were purified and tested by enzyme-
linked immunosorbent assay (ELISA) for binding to the
5T33MM Igs or control Igs, as previously described [26].
The insert peptide sequence from selected phage, the
percentage of clonal identity, and KD values of identified
synthetic Id-peptides are shown in Table 1. Based on the
highest affinity binding to 5T33MM Igs, the insert amino
acid sequence of phage clone 5 (CIGNSNTLC) was used
for large-scale synthesis of the p5 peptide in order to
evaluate the binding properties outside of the phage
context. To this end, the biotinylated-p5 peptide was incu-
bated with 5T33MM-Igs coated plates at different concen-
trations, and revealed with streptavidin-conjugated alkaline
phosphatase. The p5 peptide showed a concentration-
Fig. 3 In vitro characterization of exosome preparations. a Scanning electron microscopy (SEM). The 5T33MM cell culture supernatant was filtered
(0.22 μm) and the exosomes were purified using the ExoQuick-TC™. The SEM analysis was performed at 20, 000 x magnification (SEM FEI Novalab 600).
b Size distribution of the exosomes population derived from 5T33MM cells using dynamic light scattering (Zetasizer Nano S, Malvern Instruments). c
B-cells from the blood of multiple myeloma patient and 5T33MM cells as well as purified exosomes from patient serum or 5T33MM cell supernatant
were lysed in RIPA buffer, separated by SDS-PAGE, and analyzed by Western blotting using the indicated antibodies
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dependent specific reactivity to the cognate antibody, and
did not react against an A20 secreted IgG or polyclonal
mouse Igs (Fig. 2a).
By flow cytometry, we analyzed the specific binding of
FITC-conjugated p5 peptide to the 5T33MM, A20 and
IM9 cells expressing the surface Ig-BCR. An irrelevant
peptide (CGGNGPGLC) was included as a negative con-
trol (pCNT). The p5 peptide recognized 5T33MM target
cells in a dose-dependent manner, while the pCNT
peptide did not (Fig. 2b). The specific Id-peptide binding
to 5T33MM was verified by testing other B-cells, includ-
ing the IM9 and A20 cell lines and primary B cells from
a multiple myeloma patient and healthy donor
(Additional file 1: Figure S1). To visualize the binding of
the p5 peptide to the surface Igs, we performed confocal
microscopy of 5T33MM cells stained with the FITC-
conjugated p5 peptide and the anti-mouse IgG detecting
the surface Igs. The p5 peptide bound to the 5T33MM
cell surface and also localized inside the cells (Fig. 2c).
Since this analysis was conducted on focal planes of
non-permeabilized cells, the intracellular localization of
the p5 peptide was a likely consequence of the BCR-
mediated internalization.
Exosomes were then purified from the supernatant of
cultured 5T33MM, A20 and IM9 cells and from serum
of MM patient and healthy donor. By scanning electron
microscopy (SEM), the exosomes had a rounded shape
(30–120 nm diameter) with some agglomerations occur-
ring in the drying process during sample preparation
(Fig. 3a). Confirmation of the size homogeneity of vesi-
cles was verified using a Zetasizer Nano ZS90 (Fig. 3b).
Purified exosomes were also analyzed by Western
Fig. 4 Flow cytometry of purified exosomes derived from cultured B-cells. Exosomes were purified from supernatants of the murine 5T33MM and
human IM9 multiple myeloma cells, and the murine A20 B-lymphoma cells. The production of IgG-bearing exosomes was similar in the three cell
lines. The p5 peptide recognized specifically the 5T33MM-released exosomes. Front/side scattering of exosome-bound SMNPs (External plot); Exo-Red-stained
exosomes incubated with FITC-conjugated anti-IgG (left plots); Exo-Red-stained exosomes incubated with FITC-conjugated p5 peptide
(central plots); Exo-Red-stained exosomes incubated with FITC-conjugated pCNT (right plots)
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blotting using antibodies against typical exosomal
markers, such as CD81, CD63, including anti-IgG anti-
body to verify the IgG expression on TDEs (Fig. 3c).
To validate the reliability of the p5 peptide in targeting
the 5T33MM-released exosomes, we used an immuno-
capture approach based on anti-CD63 decorated strepta-
vidin magnetic nanoparticles (SMNPs) to trap exosomes
[27]. The size of the exosomes-functionalized SMNPs
(9.1 μm of diameter) supported the use of flow cytomet-
ric detection. Front/side scattering (FSC/SSC) plot of
RedExo-labeled and un-labeled exosomes is shown in
Fig. 4a. 5T33MM–derived exosomes were equally
detected using anti-mouse IgG or FITC-conjugated p5
peptide, while undetected when stained with control
Fig. 5 Tumor progression and serum exosomes production in tumor-engrafted mice. a Kaplan-Meier survival curves in 5T33MM-engrafted mice
(n = 10), A20-engrafted mice (n = 10) and un-grafted control mice (n = 10). b Determination of serum paraprotein (IgG2b) concentration in
5T33MM- or A20-engrafted mice and control mice measured by ELISA. c Flow cytometric analysis of Red-Exo-stained exosomes derived from
serum of a representative 5T33MM-engrafted mouse incubated with FITC-conjugated p5 peptide. d Flow cytometric analysis of Red-Exo-stained
exosomes derived from serum of a representative A20-engrafted mouse incubated with FITC-conjugated p5 peptide
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peptide, or left unstained (Fig. 4b-e). As controls, the
FITC-conjugated p5 peptide did not detect the exosomes
released from the human IM9 multiple myeloma and
murine A20 B-lymphoma cells (Fig. 4). Further, this
analysis provided the evidence of similarity between
murine and human multiple myeloma derived-exosomes
in terms of IgG expression (Fig. 4).
For translating the analysis of MM-released exosomes
to in vivo preclinical models, two groups of 10 mice were
respectively intravenously inoculated with 5T33MM cells
and with A20 cells. A third group of 10 un-injected mice
were used as negative control. At day 0 and each 7 days,
blood samples were collected by retro-orbital bleeding for
measuring the serum MM-released exosomes and para-
protein levels. According to the Kaplan–Meier survival
curve the fatal outcome of mice progressively occurred
between 21 and 40 days post cells injection (Fig. 5a). By
ELISA, the serum paraprotein was detected 21 days after
tumor inoculation (Fig. 5b). Exosomes were purified from
serum samples, conjugated with SMNPs and analyzed by
flow cytometry using the FITC-conjugated p5 peptide.
Among 5T33MM serum-derived exosomes, we identified
a p5 peptide-positive exosome sub-population 7 days after
tumor inoculation, which increased in a time-dependent
manner until death (Fig. 5c). Serum-derived exosomes
from A20 harboring mice were also purified and used
as control (Fig. 5d). The percentage of p5-FITC posi-
tive TDEs population in all mice is reported in the
Additional file 1: Table S1. These results indicated
that analysis of serum MM-released exosomes allowed
an earlier detection of MM growth compared to the
conventional measure of paraprotein.
Conclusion
In conclusion, we describe the development of a method
allowing the rapid and simple detection of MM-released
exosomes using the Id-peptide binders of the Igs
expressed by tumor B-cells. Being the IgBCR expressed
on the surface of tumor B cells as well as tumor-derived
exosomes, our methodology could be extended to the
most common B cell neoplasia with potential application
for monitoring the minimal residual disease. Further-
more, compared with the standard exosome purification
and immuno-capturing systems, the advantage of our
method relies on the use of fluorescent-labeled
Id-peptides coupled to SMNPs, which represent a more
powerful and sensitive tool for tumor detection. Based
on specificity, flexibility, cost effectiveness and modular-
ity, our capture system is ideal for novel non-invasive
applications in personalized medicine and could be eas-
ily extended to other B-cell malignancies. Our experi-
mental approach could open new avenues in devising
lab-on-a-chip platforms and liquid biopsy options for an
effective early detection of TDEs shed into the blood by
tumor B-cells.
Additional file
Additional file 1: Table S1. Percentage of p5-FITC positive TDEs population
after tumor cells injection. Figure S1. Flow cytometry analysis of
purified exosomes derived from different cell sources (DOC 570 kb)
Abbreviations
ELISA: Enzyme-linked immunosorbent assay; FITC: Fluorescein isothiocyanate;
FSC/SSC: Front/side scattering; Id-peptides: Idiotype peptides; Ig-BCR: B-cell
receptor; Igs: Immunoglobulins; mIg: monoclonal immunoglobulin;
MM: Multiple myeloma; pCNT: Irrelevant peptide; RPLs: Random peptide
libraries; SEM: Scanning electron microscope; SMNPs: Streptavidin magnetic
nanoparticles; TDEs: Tumor-derived exosomes
Acknowledgments
The authors thank Prof. Karin Vanderkerken (Department of Hematology and
Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels,
Belgium) for the 5T33MM tumor cells, and Dr. Donato Cosco (Department of
Health Sciences, University of Catanzaro “Magna Græcia” Catanzaro, Italy) for
the assistance with the Zetasizer. A special thanks to Prof. Mary Bebawy
(Laboratory Cancer Cell Biology and Therapeutics – University of Technology
Sydney) for reading the manuscript.
Grant support
Associazione Italiana per la Ricerca sul Cancro to G.S. (Grant IG-2009- 9411; IG
Grant 2012–13,388); Ministero dell’Istruzione, dell’Università e della Ricerca to G. S
and I.Q. (PRIN project 2012CK5RPF; PRIN project 2012CK5RPF_002); Grant POR
CALABRIA FSE 2007/2013 PON01/00862 to GS; Ministero della Salute Ministero
della Salute to G.S. (Grant RF-2010-2,306,943). S. M. was supported by a fellowship
from Associazione Italiana per la Ricerca sul Cancro (AIRC, FIRC).
Authors’ contributions
E.I. designed and conducted the research, analyzed the data, and wrote the
manuscript; S.M. helped in the conduction of the research plan and assisted
with the data analysis; V.D. performed the workflow illustration; F.M. assisted
with the confocal microscopy analysis; P.C. works at the SEM experiments;
D.M. helped in the data analysis; A.D.L., E.V., T.G., and S.C. assisted with the
mouse experiments; A.P., F.A., A.L., D.M, and G.F. worked at the biochemical
analysis; I.Q. and G.S. supervised the research plan and data analysis, and
reviewed the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Experimental and Clinical Medicine, University of Catanzaro
“Magna Graecia,”, Catanzaro, Italy. 2Stem Cell and Cellular Therapy Laboratory,
G. Gaslini Institute, Genoa, Italy.
Received: 20 June 2017 Accepted: 9 October 2017
References
1. Moreau P, Attal M, Facon T. Blood. 2015;125(20):3076–84.
2. Krishnan SR, Jaiswal R, Brown RD, Luk F, Bebawy M. Int J Oncologia. 2016;
49(1):33–50.
3. Yao J, Yang M, Duan Y. Chem Rev. 2014;114(12):6130–78.
4. Pan BT, Teng K, Wu C, Adam M, Johnstone RM. J Cell Biol. 1985;101:942–8.
5. Marimpietri D, Petretto A, Raffaghello L, Pezzolo A, Gagliani C, Tacchetti C,
Mauri P, Melioli G. Pistoia V. PLoS One. 2013;8(9):e75054.
Iaccino et al. Molecular Cancer  (2017) 16:159 Page 8 of 9
6. Krishnan SR, Luk F, Brown RD, Suen H, Kwan Y, Bebawy M. Neoplasia.
2016;18(1):25–32.
7. Lasser C, Alikhani VS, Ekstrom K, Eldh M, Paredes PT, Bossios A, Sjostrand M,
Gabrielsson S. Lotvall J and Valadi H. J Transl Med. 2011;9:9.
8. Théry C, Amigorena S, Raposo G. Clayton A. Curr Protoc Cell Biol. 2006;3:3.22.
9. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Nat Cell Biol.
2007;9:654–9.
10. Muratori C, Cavallin LE, Krätzel K, Tinari A, De Milito A, Fais S, Mesri EA,
Superti F, Baur AS. Cell Host Microbe. 2009;6:218–30.
11. Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Sci Rep.
2016;6:20254.
12. Harris DA, Patel SH, Gucek M, Hendrix A, Westbroek W, Justin W. Taraska.
PLoS One. 2015;10(3):e0117495.
13. Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Ogino S, Fujita Y,
Hiramoto H, Hamada J, Okamoto K, Otsuji E. Oncotarget. 2016;7(35):56855–63.
14. Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, Manier S,
Roccaro AM. Methods Mol Biol. 2016;1464:25–34.
15. Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-'t Hoen EN,
Piper MG, Sivaraman S, Skog J, Théry C, Wauben MH, Hochberg F. J Extracell
Vesicles. 2013;27:2.
16. Colombo M, Raposo G, Théry C. Annu Rev Cell Dev Biol. 2014;30:255–89.
17. Saunderson SC, Schuberth PC, Dunn AC, Miller L, Hock BD, MacKay PA, Koch
N, Jack RW, McLellan AD. J Immunol. 2008;180(12):8146–52.
18. Gutzeit C, Nagy N, Gentile M, Lyberg K, Gumz J, Vallhov H, Puga I, Klein E,
Gabrielsson S, Cerutti A, Scheynius A. J Immunol. 2014;192(12):5852–62.
19. Schiavone M, Fiume G, Caivano A, de Laurentiis A, Falcone C, Masci FF,
Iaccino E, Mimmi S, Palmieri C, Pisano A, Pontoriero M, Trovato M, Rafay J,
Ferko B, Morsica G, Poli G, Quinto I, Pavone V, de Berardinis P, Scala G. Int J
Mol Sci. 2012;13(5):5674–99.
20. Tuccillo FM, Palmieri C, Fiume G, de Laurentiis A, Schiavone M, Falcone C,
Iaccino E, Galandrini R, Capuano C, Arra C, Barbieri A, Dal Piaz F, Venzon D,
Bonelli P, Buonaguro FM, Scala I, Mallardo M, Quinto I, Scala G. Mol Cancer
Ther. 2014;13(3):752–62.
21. Mangini M, Iaccino E, Mosca MG, Mimmi S, D'Angelo R, Quinto I, Scala G,
Mariggiò S. Oncotarget. 2017;8(3):5179–95.
22. Causa F, Della Moglie R, Iaccino E, Mimmi S, Marasco D, Scognamiglio PL,
Battista E, Palmieri C, Cosenza C, Sanguigno L, Quinto I, Scala G, Netti PA. J
Colloid Interface Sci. 2013;389(1):220–9.
23. Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De
Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico
MR, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C,
Giudice A, Palma G, Barbieri A, Quinto I, Scala G. Blood. 2010;116(2):226–38.
24. Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E,
Vanderkerken K. Adv Cancer Res. 2011;110:19–42.
25. De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De
Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van
Valckenborgh E, Vanderkerken K. J Pathol. 2017;241(4):534–46.
26. Mimmi S, Vecchio E, Iaccino E, Rossi M, Lupia A, Albano F, Chiurazzi F,
Fiume G, Pisano A, Ceglia S, Pontoriero M, Golino G, Tassone P, Quinto I,
Scala G, Palmieri C. Leukemia. 2016;30(12):2419–22.
27. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, Liu J, Pan T, Chen J, Wu M, Zhou X,
Yuan Z. Nat Immunol. 2013;14(8):793–803.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Iaccino et al. Molecular Cancer  (2017) 16:159 Page 9 of 9
